ReviewCancer cell international2021
The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review.
Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).Oncology research · 2026Pooled it
- Periodontitis as a risk factor for colorectal cancer: systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2025Pooled it
- Is the oral pathogen, Porphyromona gingivalis, associated to colorectal cancer?: a systematic review.BMC cancer · 2025Pooled it
- Trial
- Article
- Unveiling the Gastric Microbiome: Novel Insights into Early Detection and Pathogenesis of Gastric Cancer.Probiotics and antimicrobial proteins · 2026Review
- Probiotics Exert Colonization Resistance AgainstMicroorganisms · 2026Article
- Pyroptosis as a double-edged sword in colorectal cancer: Molecular mechanisms and therapeutic opportunities.Apoptosis : an international journal on programmed cell death · 2026Review
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- Disordered colonic microbiota as a potential contributor to inflammation in diarrheal Jinhua weaned piglets.Animal microbiome · 2026Article
- The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.Frontiers in immunology · 2026Review
- Nutrition and the gut microbiome: a symbiotic dialogue influencing health and disease.Frontiers in nutrition · 2026Review
- Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities.Frontiers in immunology · 2026Review
- Progress on the regulation of colorectal cancer and cardio-oncology by the gut microbiota and nutrients.Frontiers in immunology · 2026Review
- Unveiling hidden players: the role of intratumoral microbiota in gastrointestinal cancer dynamics.Journal of cancer research and clinical oncology · 2025Review
- The association of proton pump inhibitors and inflammatory bowel disease from the perspective of gut microbiota perturbation.NPJ biofilms and microbiomes · 2025Review
- Characterization of the microbial profile in tears of patients with primary open-angle glaucoma: results from a pilot study.Scientific reports · 2025Article
- Altered Development of Gut Microbiota and Gastrointestinal Inflammation in Children with Post-Operative Hirschsprung's Disease.International journal of molecular sciences · 2025Article
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cause of cancer globally and the fourth attributable cause of mortality and morbidity due to cancer. An emerging factor contributing to CRC is the gut microbiota and the cellular changes associated with it. Further insights on this may help in the prevention, diagnosis and new therapeutic approaches to colorectal cancer. In most cases of CRC, genetic factors appear to contribute less to its aetiology than environmental and epigenetic factors; therefore, it may be important to investigate these environmental factors, their effects, and the mechanisms that may contribute to this cancer. The gut microbiota has recently been highlighted as a potential risk factor that may affect the structural components of the tumor microenvironment, as well as free radical and enzymatic metabolites directly, or indirectly. Many studies have reported changes in the gut microbiota of patients with colorectal cancer. What is controversial is whether the cancer is the cause or consequence of the change in the microbiota. There is strong evidence supporting both possibilities. The presence of Fusobacterium nucleatum in human colorectal specimens has been demonstrated by RNA-sequencing. F. nucleatum has been shown to express high levels of virulence factors such as FadA, Fap2 and MORN2 proteins. Our review of the published data suggest that F. nucleatum may be a prognostic biomarker of CRC risk, and hence raises the potential of antibiotic treatment of F. nucleatum for the prevention of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.